What does “Lynparza LOE” mean?
“Lynparza” is the brand name for olaparib. In pharma contexts, LOE usually means “loss of exclusivity”—the point when a company’s legal/market exclusivity for a product ends, which can open the door to generic or biosimilar competition (depending on the product type and what protections have expired).
The exact LOE timing for Lynparza depends on the specific country and the specific protection being referenced (for example, patents covering formulations, dosing regimens, or specific combinations).
When is Lynparza’s loss of exclusivity?
Patent and exclusivity timelines vary by geography and by the specific Lynparza indication and formulation. To get the most accurate LOE estimate, you typically need:
- the country (e.g., US vs. EU vs. UK),
- whether you mean olaparib tablets vs capsules,
- and which patent/patent family is being tracked.
DrugPatentWatch.com tracks exclusivity and patent-related timelines for branded drugs and can be used to look up Lynparza’s relevant dates.
You can check Lynparza here: DrugPatentWatch.com – Lynparza (olaparib)
Are LOE dates different for different Lynparza uses?
Yes. Even for the same medicine, exclusivity can differ based on:
- the indication (some protections are tied to a cancer type or biomarker strategy),
- the treatment combination (for example, with another drug),
- and which patents were granted and when they expire.
That means you may see different “LOE” dates depending on what the source is measuring.
Is Lynparza protected by patents or regulatory exclusivity too?
Typically both can matter:
- patents can extend exclusivity for specific claims (formulations, methods of use, combinations), and
- regulatory exclusivities can also delay generic entry even after some patents expire, depending on jurisdiction and product type.
So “LOE” is usually a composite outcome of multiple protection layers.
Quick check: what exactly do you need?
If you tell me the country (US, EU, UK, etc.) and whether you mean tablets/capsules or a specific indication, I can help interpret what “Lynparza LOE” would refer to and point you to the right timeline basis.
Sources
- DrugPatentWatch.com – Lynparza (olaparib)